Trial
NCT04427306
Neoadjuvant T-VEC in High Risk Early Melanoma
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
University of California, Davis
Collaborators
Amgen
Condition
Melanoma
Intervention
T-Vec
Why stopped
low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-15